CoRe-T: The CD6/CTLA4 CAR-Treg. A First-in-class T-cell Targeting and Treg Specific Signalling Treg Therapy
- Introduction to CoRe-T (Counter Regulatory) CAR-Tregs: The CD6/CTLA-4 CAR-Treg
- Overview of Clinical Data in Chronic Refractory GvHD patients
- Shaping the future of targeted Treg therapies with multi-edited allogenic CAR-Tregs.
- Updates on PolTREG’s clinical pipeline and EMA’s agreement to receive submission of a Marketing Authorization for PTG-007 + Rituximab in Stage 3 T1D